Sichuan Kelun-Biotech Biopharmaceutical (HKG:6990) will present the results of its phase 1/2 study of its sacituzumab tirumotecan drug during a meeting of the American Society of Clinical Oncology in San Francisco from Thursday to Saturday.
The drug is indicated for patients with locally advanced or metastatic urothelial carcinoma who have shown progress on or after prior anti-cancer treatments, according to a Tuesday filing with the Hong Kong exchange.
The drug has previous indications for advanced solid tumors such as non-small cell lung cancer, breast cancer, gastric cancer, and gynecological tumors, among others, the filing said.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。